ERBB2 and ductal breast carcinoma in situ: HER2 could also be a target for breast cancer prevention because HER2 is overexpressed in a majority of ductal carcinoma in situ (DCIS) cases of the breast, a non-obligate precursor of invasive breast cancer [9,10,11].